John G. Pazin

John Pazin practices at Wexford Hospital in Wexford, Pennsylvania, part of Highmark Health.

John Pazin's NPI, 1154356525, was assigned on July 12, 2006. John Pazin graduated from Duke University School of Medicine in 1996. John Pazin holds Pennsylvania license MD068422L.

John Pazin's primary practice is Wexford Hospital, at 12351 Perry Highway, Wexford, PA 15090 in Allegheny County. The practice phone is (412) 295-3319.

John Pazin's primary practice is Wexford Hospital in Wexford, Pennsylvania, part of Highmark Health. John Pazin is also affiliated with UPMC Magee-Womens Hospital. The medical group on file is AHN Primary Care - Family Med Associates at H+W Pavilion Bethel Park. Dmand AI also links John Pazin to 3 more hospitals, 3 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where John Pazin practices, 9 sites in all. Vendor and product names are available with a free account.

Internal medicine is John Pazin's primary specialty in the NPI Registry, under taxonomy code 207R00000X. John Pazin is board certified in internal medicine by the American Board of Internal Medicine. John Pazin is licensed in Pennsylvania.

CMS data shows 863 Medicare services from John Pazin across 11 procedure codes in 2024, for 284 Medicare patients. Medicare paid $83,037 for them. Every service was in an office.

CMS counts 284 Medicare patients who saw John Pazin in 2024. The largest group is 65 to 74, with 190 patients. 75% of them have high cholesterol, and 64% have high blood pressure. Their average risk score is 0.96, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts John Pazin's median patient age at 71, with 42% women.

In 2024, John Pazin wrote 9,002 Medicare Part D claims for 636 patients. 89% of them were for generic drugs. CMS names the drug for 8,379 of them, across 130 drugs with 11 or more claims each, at $547,306 in total drug cost. In 2023, CMS named 8,120 claims across 128 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for John Pazin for performance year 2024, reported through an alternative payment model (APM). John Pazin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists John Pazin as offering telehealth.

CMS Open Payments shows 349 general payments to John Pazin from 33 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,116.

John Pazin graduated from Duke University School of Medicine in 1996.